LJPC


These 3 Penny Stocks Have Massive Upside Potential, Says Cowen

It’s a mixed bag when it comes to opinions on penny stocks. These tickers trading for less than $5 per share divide Wall …

La Jolla (LJPC) Stock Crashes — Is There a Light at the End of the Tunnel?

La Jolla’s (LJPC) shares lost almost half of their value Monday, after the company pre-announced fourth quarter revenues for its drug Giapreza – …

Phil Nadeau Continues to Highlight La Jolla Pharmaceutical Company (LJPC) as “Undervalued” on Back of Giapreza’s Early FDA Victory

Cowen’s Phil Nadeau looks for “rapid adoption” in La Jolla’s Giapreza’s approved wider indication to hike up blood pressure in refractory patients.

La Jolla Pharmaceutical Company (LJPC): Why Cowen Analyst Sees More Upside

La Jolla Pharmaceutical Company (NASDAQ:LJPC) investors are overwhelmingly excited today after the drug maker reported compelling results from a phase 3 trial of its hypotension …

Monday’s Market Insights: HTG Molecular Diagnostics Inc (HTGM), La Jolla Pharmaceutical Company (LJPC), Shutterstock Inc (SSTK)

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) shares skyrocketed today, up by 135% as of 02:35 p.m.

Company Update (NASDAQ:LJPC): La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501

La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, …

Company Update (NASDAQ:LJPC): La Jolla Pharmaceutical Company Announces Third Quarter 2015 Financial Results and Recent Corporate Progress

La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, …

Chardan Raises Price Target For La Jolla Pharmaceutical Company Following Meeting with CEO

Chardan Capital analyst Gbola Amusa weighed in today with a favorable report on La Jolla Pharmaceutical Company (NASDAQ:LJPC), reiterating a Buy rating and raising the price target …

Stock Update (NASDAQ:LJPC): La Jolla Pharmaceutical Company and Vanderbilt University Enter Exclusive Research and License Agreement Covering Novel BMP Type-I Receptor Inhibitors

La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts